Washington, DC (December 22, 2022) – The independent, non-profit Alliance for Cell Therapy Now applauds Congress for inclusion of several provisions within the FY 2023 Omnibus Spending Bill that will advance the development and manufacturing of cell-based therapies. Key provisions included:

  • Recognition that adult cell-based therapies hold promise for a broad range of conditions, including neurological conditions, musculoskeletal conditions, cancer, radiation damage, cardiovascular disease, diabetes, wound healing, and immunological disease.
  • Encouraging NIH to support research, development, and manufacturing of adult cell-based therapies for patients with serious or life-threatening conditions.
  • Encouraging the NIH to support clinical trials and pre-clinical research exploring the use of adult cell-based therapies for serious or life-threatening conditions; support development, characterization, optimization, and scaling of manufacturing of cell-based therapies; support sharing of best practices and lessons learned; and workforce development activities.
  • Encouraging NIH to support collaborative evidence development, including continued NIH collaboration with FDA and HRSA to enhance transparency regarding outcomes from cellular therapies from adult (somatic) cells that are FDA-approved or being administered under FDA IND or IDE protocols.

About Alliance for Cell Therapy Now 

Alliance for Cell Therapy Now is an independent, non-profit organization guided by leaders representing academic and medical institutions, industry innovators, and patients, that is working to advance safe and effective regenerative medicine and cell therapies for patients in need. For more information about the Alliance, go to https://allianceforcelltherapynow.org/.